Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | THPO | P40225 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853713 | 0.77 | ALDH1A1 (0.53) | CYP3A4TSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7506388 | 0.75 | EGFR (0.45) | CYP3A4TSHREGFRERBB2ALDH1A1 | |
| SCHEMBL3163386 | 0.73 | CYP3A4 (0.54) | CYP3A4TSHRALDH1A1HIF1AMAPT | |
| SCHEMBL4067057 | 0.73 | CYP3A4 (0.42) | CYP3A4TSHRSMN1; SMN2LMNAMAPT | |
| SCHEMBL15430 | 0.72 | CYP3A4 (0.70) | CYP3A4TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL8816989 | 0.72 | HDAC6 (0.49) | CYP3A4TSHREGFRERBB2ALDH1A1 | |
| SCHEMBL8681145 | 0.72 | ALDH1A1 (0.50) | CYP3A4TSHREGFRERBB2ALDH1A1 | |
| SCHEMBL896520 | 0.71 | ALDH1A1 (0.61) | CYP3A4TSHREGFRERBB2ALDH1A1 | |
| SCHEMBL3989130 | 0.71 | CYP3A4 (0.63) | CYP3A4TSHRGABRA1GABRB2TDP1 | |
| SCHEMBL28702916 | 0.70 | ALDH1A1 (0.56) | CYP3A4TSHREGFRERBB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | claimed |
| EP-0484870-A2 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1992-05-13 | — | — | EP | claimed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-8236985-B2 | Compounds and uses thereof | IMPERIAL INNOVATIONS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-5773435-A | ANTITUMOR AGENTS USING CEPHALOSPORINS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0742015-A1 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0484870-A2 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0192242-B1 | SUBSTITUTED AMINOPHENYLUREA DERIVATIVES | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4803223-A | ANTITUMOR AGENTS | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0192242-A1 | Substituted aminophenylurea derivatives | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1986-08-27 | — | — | EP | disclosed |
| US-3932318-A | COPOLYMERS WITH ISOCYANATES, CRYOGENIC POLYMERIZATION, NONFLAMMABLE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | CYP3A4 1084/4885TSHR 3550/4885EGFR 896/4885 |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | CYP3A4 3812/4885TSHR 3707/4885EGFR 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.